Mark Lebwohl1, Andrew Blauvelt2, Carle Paul3, Howard Sofen4, Jolanta Węgłowska5, Vincent Piguet6, Daniel Burge7, Robert Rolleri8, Janice Drew7, Luke Peterson8, Matthias Augustin9. 1. Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: lebwohl@aol.com. 2. Oregon Medical Research Center, Portland, Oregon. 3. Paul Sabatier University, Toulouse, France. 4. David Geffen School of Medicine, University of California, Los Angeles, California. 5. Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław, Poland. 6. University Hospital of Wales, Cardiff University, Cardiff, United Kingdom; Women's College Hospital, University of Toronto, Toronto, Canada. 7. Dermira Inc, Menlo Park, California. 8. UCB Pharma, Raleigh, North Carolina. 9. University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract
BACKGROUND: Phase 2 psoriasis studies with the Fc-free, PEGylated, anti-tumor necrosis factor biologic certolizumab pegol demonstrated meaningful clinical activity. OBJECTIVE: Assess safety and efficacy of certolizumab in adults with moderate-to-severe chronic plaque psoriasis. METHODS: Patients were randomized 3:3:1:3 to certolizumab 400 mg, certolizumab 200 mg, or placebo every 2 weeks for 16 weeks or etanercept 50 mg twice weekly for 12 weeks. Certolizumab-treated patients achieving a ≥75% reduction in Psoriasis Area and Severity Index (PASI) at week 16 from baseline PASI were rerandomized to certolizumab or placebo for 32 weeks. The primary endpoint was responder rate (≥75% reduction in PASI from baseline PASI) versus placebo (primary analysis) and etanercept (secondary analysis) at week 12; secondary endpoints included responder rates on various measures versus placebo at weeks 12, 16, and 48. Safety was assessed by treatment-emergent adverse events. RESULTS: All endpoints were significantly greater for certolizumab versus placebo with the greatest response seen with 400 mg. Certolizumab 400 mg was superior to and 200 mg was noninferior to etanercept. Adverse events were consistent with the anti-tumor necrosis factor class of drugs. LIMITATIONS: Etanercept was administered by unblinded study staff or self-administered, but efficacy assessments were performed by a blinded assessor. CONCLUSION: Both certolizumab regimens improved psoriasis symptoms, with a greater response seen with the higher dose. No new safety signals were observed.
RCT Entities:
BACKGROUND: Phase 2 psoriasis studies with the Fc-free, PEGylated, anti-tumornecrosis factor biologic certolizumab pegol demonstrated meaningful clinical activity. OBJECTIVE: Assess safety and efficacy of certolizumab in adults with moderate-to-severe chronic plaque psoriasis. METHODS:Patients were randomized 3:3:1:3 to certolizumab 400 mg, certolizumab 200 mg, or placebo every 2 weeks for 16 weeks or etanercept 50 mg twice weekly for 12 weeks. Certolizumab-treated patients achieving a ≥75% reduction in Psoriasis Area and Severity Index (PASI) at week 16 from baseline PASI were rerandomized to certolizumab or placebo for 32 weeks. The primary endpoint was responder rate (≥75% reduction in PASI from baseline PASI) versus placebo (primary analysis) and etanercept (secondary analysis) at week 12; secondary endpoints included responder rates on various measures versus placebo at weeks 12, 16, and 48. Safety was assessed by treatment-emergent adverse events. RESULTS: All endpoints were significantly greater for certolizumab versus placebo with the greatest response seen with 400 mg. Certolizumab 400 mg was superior to and 200 mg was noninferior to etanercept. Adverse events were consistent with the anti-tumornecrosis factor class of drugs. LIMITATIONS: Etanercept was administered by unblinded study staff or self-administered, but efficacy assessments were performed by a blinded assessor. CONCLUSION: Both certolizumab regimens improved psoriasis symptoms, with a greater response seen with the higher dose. No new safety signals were observed.
Authors: April W Armstrong; Ahmed M Soliman; Keith A Betts; Yan Wang; Yawen Gao; Luis Puig; Matthias Augustin Journal: Dermatol Ther (Heidelb) Date: 2021-03-31
Authors: Michael J Grayling; Theophile Bigirumurame; Svetlana Cherlin; Luke Ouma; Haiyan Zheng; James M S Wason Journal: BMC Rheumatol Date: 2021-07-02
Authors: R B Warren; M Lebwohl; H Sofen; V Piguet; M Augustin; F Brock; F Fierens; A Blauvelt Journal: J Eur Acad Dermatol Venereol Date: 2021-08-17 Impact factor: 9.228
Authors: A Blauvelt; C Paul; P van de Kerkhof; R B Warren; A B Gottlieb; R G Langley; F Brock; C Arendt; M Boehnlein; M Lebwohl; K Reich Journal: Br J Dermatol Date: 2020-09-06 Impact factor: 9.302